chrisvoncsefalvay/vaers-outcomes huggingface dataset:
2.5 inch welt or hive at injection site; 2.5 inch welt or hive at injection site; a orange sized swelling in armpit of left arm,; muscle fatigue; pain across pectoral muscles; Itchy red skin up and down left arm and neck.; Itchy red skin up and down left arm and neck.; Itchy red skin up and down left arm and neck.; Nausea; Dose 3 (07Sep2022); Dose 4 (07Sep2022); This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 07Sep2022 at 19:00 as dose 4 (booster), single (Lot number: GHG9694), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing), notes: other medical history: Asthma; "allergies" (unspecified if ongoing), notes: other medical history:allergies; "Known allergies: Pomogranate" (unspecified if ongoing); "Known allergies: red 40" (unspecified if ongoing). Concomitant medication(s) included: FLULAVAL QUADRIVALENT, on 01Sep2022. Vaccination history included: BNT162b2 (Product: Pfizer, Batch / lot number: FF2593, Dose number: 3, Vaccine location: Right arm), administration date: 07Sep2022, for Covid-19 immunization, reaction(s): "2.5 inch welt or hive at injection", "2.5 inch welt or hive at injection", "a orange sized swelling in armpit of left arm", "muscle fatigue", "pain across pectoral muscles", "Itchy red skin up and down left arm and neck", "Itchy red skin up and down left arm and neck", "Itchy red skin up and down left arm and neck", "Nausea"; Covid-19 vaccine (Primary immunization series complete, Covid-19 vaccine[unknown manufacturer]), for Covid-19 immunization.  The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 07Sep2022, outcome "unknown", described as "Dose 3 (07Sep2022); Dose 4 (07Sep2022)"; VACCINATION SITE REACTION (non-serious), INJECTION SITE URTICARIA (non-serious), outcome "recovering" and all described as "2.5 inch welt or hive at injection site"; SWELLING (non-serious), outcome "recovering", described as "a orange sized swelling in armpit of left arm,"; MUSCLE FATIGUE (non-serious), outcome "recovering"; MYALGIA (non-serious), outcome "recovering", described as "pain across pectoral muscles"; PRURITUS (non-serious), ERYTHEMA (non-serious), ERYTHEMA (non-serious), outcome "recovering" and all described as "Itchy red skin up and down left arm and neck."; NAUSEA (non-serious), outcome "recovering". Therapeutic measures were not taken as a result of vaccination site reaction, injection site urticaria, swelling, muscle fatigue, myalgia, pruritus, erythema, erythema, nausea.  Additional information: Patient did not have COVID prior vaccination and patient did not test COVID post vaccination.
Earache in her right ear and it hurts when she puts her chin down.; Swollen lymph nodes; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 71 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 10Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "allergies to grasses" (unspecified if ongoing); "allergies to mold" (unspecified if ongoing); "lost her hearing" (unspecified if ongoing), notes: She states she lost her hearing in her right ear a year ago. The patient's concomitant medications were not reported. The following information was reported: EAR PAIN (non-serious) with onset Mar2021, outcome "unknown", described as "Earache in her right ear and it hurts when she puts her chin down."; LYMPHADENOPATHY (non-serious) with onset Mar2021, outcome "unknown", described as "Swollen lymph nodes".  Additional information: Patient second dose is scheduled for 30Mar2021. She states that shortly after receiving her first dose of the vaccine she developed an earache in her right ear, and it hurts when she puts her chin down. She is wondering if she has swollen lymph nodes. She noticed that swollen lymph nodes were a possible side effects. She states she lost her hearing in her right ear a year ago. Patient stated, well she gets her second shot (Confirmed as Pfizer Covid vaccine) today, this afternoon and she was wondering, she just went down picked a paper which gets a card and she had read through the side effects and one of the side effects is swollen lymph nodes. Now she doesn't know, she gets allergies about this time of the year. She went to this store this morning, grocery shopping but it's her ear it kind of hurt and then it, sometime when she put her chin down, she can feel kind of ear canal, area underneath her chin back with the ear and which is like the allergies, she gets every year. So, she don't know, should go ahead and get the shot?". So further probing could not be done. Hence, Product details (LOT, Expiration date, NDC, UPC) and other patient details were unknown. Patient Seriousness Criteria-Caused/prolonged hospitalization: No. Patient Seriousness Criteria-Congenital anomaly/birth defect: No. Patient Seriousness Criteria-Disabling/Incapacitating: No. Patient Seriousness Criteria-Results in death: No. Patient Seriousness Criteria-Life threatening: No.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
erythema 3" by 3" raised and red hot.; erythema 3" by 3" raised and red hot.; erythema 3" by 3" raised; This case was reported by a consumer via interactive digital media and described the occurrence of erythema in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced erythema, feeling hot and swelling. On an unknown date, the outcome of the erythema, feeling hot and swelling were unknown.   It was unknown if the reporter considered the erythema, feeling hot and swelling to be related to Shingrix.  Additional details were provided as follows: The patient received 1st dose of Shingrix immunization caused a raised area of erythema which was quite hot and measured about 3" by 3". The patient inquired that  could he get the 2nd dose of Shingrix after 2 months or it was considered as an allergic reaction or normal reaction. The information regarding consent to follow up was not reported. No further information was available.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown demographics. No concurrent conditions or medical history were provided. On an unknown dates in September 2014, those patient were vaccinated with doses of PROQUAD injections (lot # K006217 with expiry date: 29-OCT-2015 or lot # K007797 with expiry date: 29-NOV-2015; doses, routes of administration and indication unspecified), that underwent a temperature excursion, on unspecified dates between 03-SEP-2014 - 30-SEP-2014. No concomitant medications were reported. No adverse experiences were reported. This is one of several reports from the same source. Additional information has been requested.
Patient came in with son for well check. Patient approved by a nurse to get a Pfizer booster. COVID-19 vaccine clinic run in pediatrics department today. Remaining vials put in medication room to use for other pediatric patients. A pediatric 0.3mL diluted with 1.3mL of sodium chloride given to patient instead of an adult dose of the 0.3mL diluted in 1.8mL of sodium chloride.
She was sick; Nausea; Vomiting; Headache; Dry face; Dry throat; This is a spontaneous report from a contactable consumer. A female patient of 55-year-old age received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 29Jun2021 as single dose for COVID-19 immunization. The patient had no medical history and concomitant medications reported. After couple of days patient experienced sick with nausea, vomiting, headache, dry face, and a dry throat. The patient was concerned about receiving the second dose. The outcome of all events was unknown.  Information on the lot/batch number has been requested.
rash devel approx 1wk p/vax 12APR96 started shoulder-gen w/itching;1mo duration to MD p/3wk tx w/DPH & lotion
9 days post vaccine HA dry nonproductive cough fever body aches positive (1/24/2021)
chills 915PM, sweats 110AM, localized redness;pt MD office stated these could be nl reactions;
Within 3-4 hours after injection, the site was very sore. I also experienced fatigue, headache, chills, loss of appetite.
Running fever of 100.3; This case was reported by a consumer via call center representative and described the occurrence of fever in a 72-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of pyrexia (received 1st dose on an unspecified day. For tolerance of 1st dose refer case US2020AMR023953).   On 9th February 2020, the patient received the 2nd dose of Shingrix. On 10th February 2020, 1 days after receiving Shingrix, the patient experienced fever. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the fever was not recovered/not resolved.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were provided as follows: The patient had side effects of running fever of 100.3 degrees Fahrenheit.  The patient inquired if this was common and if could attend a funeral in the evening of the day of reporting.
Developed cellulitis of upper arm after immunizatino requiring hospitalization and IV antibiotics.  Nurse follow up on 10/13/04 states: "Swelling of L upper extremity and ecchymosis in center of L deltoid - DTaP injection site. "
Patient described adverse event starting with her arm feeling sore, and hard to move. She later removed long sleeve shirt and noticed that the arm was red in color below the sight of injection and warm to touch. It later progressed to become swollen and began to move down her arm towards the elbow area. She went to a local 24 hour pharmacy around 3:30 am and was instructed by the pharmacist to began taking Benadryl 50mg by mouth every 4 hours as needed. She reported it to have helped. She continued taking it and then came into the pharmacy on 1/17/20 to show myself and the pharmacist on duty. The pharmacist advised her to continue taking the Benadryl as directed and if worried could go to an urgent care to be seen. Patient takes advice and gets seen at a local urgent care. She was given a prescription to treat adverse effect as it were cellulitis. Prescription reads Cephalexin 500mg by mouth every 12 hours for 10 days. Patient was counseled on the antibiotic and a phone call was made today (1/20/20) to ask patient how she was doing. Patient described the pain and swelling in her arm to have decreased. She said the colored changed to a brown color and appears as if it were a bruise. She described the feeling as irritated, and feeling asleep with a tingle.
PAIENT HAD INJECTION SITE TENDERNESS AND SLIGHT BRUISING FOLLOWING DAY. 10/4.  BRUISING (BLACK/ DEEP PURPLE) PATTERN PROGRESSED FROM INJECTION SITE TO WRIST. PATIENT COMMENTED ARM OF INJECTION WAS TO SORE TO SLEEP ON AND INJECTION SITE WAS HARD. BRUISING BEGAN TO DIMINISH ON 10/10/13.
Injection site cellulitis left arm developed 1 week after vaccine administration, requiring oral cephalexin.  Patient seen at regular intervals (06/27/2001, 06/29/2001,..)
pt recv vax & presented w/a 6x6 area of swelling & fever 101;this is 1 of 3 pt from the same site & lot# to exp these rxn;
Intussusception, diarrhea, vomiting, dehydration. 8/17/09 Hospital records received DOS 7/30/09 - 7/31/09. Assessment: Ileocolic intussusception. Patient presents with vomiting, irritable, pale, intermittent crying, drawing up legs, diarrhea then no stool, No PO intake, "choking on vomit". Trouble breathing. Currant jelly red stool. Dehydration.   9/23/09 ICD-9 Codes received: 560.0 Intussusception, 276.51 Dehydration.
Stinging and itching all over her body. Nausea and blood pressure keep going up. Went to urgent care
patient reports ~2 days after administration a localized rash/hives appeared on left arm on the lower deltoid area in addition to unilateral left eyelid rash that has persisted but improved till 2nd vaccine appointment. No trouble breathing or swelling of neck/face. instructed to stay 30minutes in pharmacy and administered in alternative arm (right deltoid)
Extreme dizziness, off balance, nausea. Has not let up at all. When to dr. He is sending me for mri/contrast on brain. April 28, 2021 Went to another ent Dr and he has put me on Methyiprdnisolone.
COVID arm (red swollen itchy and warm at injection site about 5 hours after vaccination). Size of swelling and redness increased to about 3 inches.
Patient did not have any reaction to vaccine but wanted to document that she was pregnant 1 week prior to vaccine.
Little headache; Couldn't breathe; Body ache; High fever; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 12-Mar-2021 and was forwarded to Moderna on 12-Mar-2021.    This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of DYSPNOEA (Couldn't breathe), PYREXIA (High fever), MYALGIA (Body ache) and HEADACHE (Little headache) in a 43-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B12A).) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, the patient experienced PYREXIA (High fever). On 08-Apr-2021, the patient experienced MYALGIA (Body ache). On 09-Apr-2021, the patient experienced DYSPNOEA (Couldn't breathe). On 12-Apr-2021, the patient experienced HEADACHE (Little headache). On 10-Apr-2021, DYSPNOEA (Couldn't breathe), PYREXIA (High fever) and MYALGIA (Body ache) had resolved. At the time of the report, HEADACHE (Little headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment included Tylenol, NyQuill pills during mornings and evenings Hot tea. Concomitant medications were not provided.
erythema multiforme w/angioedema onset 6 days p/immun w/MMR vax;
Vaccine Saturday morning.  About 24 hours after vaccine (Sunday), noticed left hand pinky red/blue/mottled dusky.  Like frostbite reaction.  No pain to suggest a bruise or injury.   Had first 2 vaccines from Moderna and booster was Pfizer.    Monday remains mottled.  Now having mild pain in L elbow.
R09.02 HYPOXIA 1/18/2022 ATHEROSCLEROSIS OF AORTA STREP PNEUMONIA R09.02 HYPOXIA 1/18/2022 HX OF SUBSTANCE USE DISORDER
hiatal hernia; condition aggravated; Was hospitalized for pain management; This case was reported by a nurse via sales rep and described the occurrence of hiatal hernia in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included hiatal hernia.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced hiatal hernia (serious criteria hospitalization), pain (serious criteria hospitalization) and condition aggravated (serious criteria hospitalization). On an unknown date, the outcome of the hiatal hernia, pain and condition aggravated were unknown.   It was unknown if the reporter considered the hiatal hernia, pain and condition aggravated to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was unknown. The patient had hiatal hernia that acted up after second Shingrix dose. The patient was hospitalised for pain management for 7 days. The reporter did not consent to follow up.
pt stated had nausea, vomiting , high fever, chills, weak in legs on 10/2 -- she stated she feels better today other than be a little weak and is contacting her doctor just to let him know of reaction and if she needs to do anything else
Two days later blood pressure was 130/90 (close to 110); He is aware that he may have Hypertension; Was aware that one of the side effects could be tiredness; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of BLOOD PRESSURE ABNORMAL (Two days later blood pressure was 130/90 (close to 110)), HYPERTENSION (He is aware that he may have Hypertension) and FATIGUE (Was aware that one of the side effects could be tiredness) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     No Medical History information was reported.    On 20-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 22-Jan-2021, the patient experienced BLOOD PRESSURE ABNORMAL (Two days later blood pressure was 130/90 (close to 110)), HYPERTENSION (He is aware that he may have Hypertension) and FATIGUE (Was aware that one of the side effects could be tiredness). At the time of the report, BLOOD PRESSURE ABNORMAL (Two days later blood pressure was 130/90 (close to 110)), HYPERTENSION (He is aware that he may have Hypertension) and FATIGUE (Was aware that one of the side effects could be tiredness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.  Patient reports Two after receiving his blood pressure was 130/90 (close to 110), blood pressure dropped again to 110/63. Did not take any medication, ate some crackers and drank class of coke for the salt. Blood pressure came back up to 128/80 and he was very tired. He is aware that he may have Hypertension but has never been clinically diagnosed with it.
2 day fever of 101, headache, deep dry cough for three days, fatigue, ongoing left arm deltoid pain, sinus pain and infection
he was tested positive after taking the 1st dose/we vaccinated a week later we both my wife and I both got COVID; This is a spontaneous report received from a Pfizer sponsored program. A male contactable consumer (reported for himself). A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number and Expiration Date was not reported) via an unspecified route of administration in on 27Jan2021, as1st dose, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. It was reported that patient took the 1st dose last on 27Jan2021. He took the 2nd dose just today 09May2021, because as per the caller he was tested positive after taking the 1st dose. Caller was advised to wait for 90 days before taking the 2nd dose. Caller was asking if he needs to start over or not. but as patient and his wife vaccinated a week later we both my wife and I both got COVID on (03Feb2021 ) and we were 3 days after that we got infusion okay, so we were told we couldn't go back for our second shot for 90 days which we just completed on this morning for the shot, so that question came up today that should be our second shot or should we stop the process over again with the first shot and that's my question to you. The out-come of the event was unknow.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) : different patients
weakness in legs; Hip pain cannot walk; Hip pain cannot walk; chill; vomit; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (weakness in legs), ARTHRALGIA (Hip pain cannot walk), GAIT DISTURBANCE (Hip pain cannot walk), CHILLS (chill) and VOMITING (vomit) in a 77-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012MZ0A and 001A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Mar-2021, the patient experienced MUSCULAR WEAKNESS (weakness in legs), ARTHRALGIA (Hip pain cannot walk), GAIT DISTURBANCE (Hip pain cannot walk), CHILLS (chill) and VOMITING (vomit). At the time of the report, MUSCULAR WEAKNESS (weakness in legs), ARTHRALGIA (Hip pain cannot walk), GAIT DISTURBANCE (Hip pain cannot walk), CHILLS (chill) and VOMITING (vomit) outcome was unknown.            No relevant concomitant medications were reported.  Treatment details included Tylenol 3 doses 4March2021, No HCP Consulted.   Most recent FOLLOW-UP information incorporated above includes: On 01-May-2021: Follow up received and contains no new information.
chronic herpes zoster; postherpetic neuralgia; This initial spontaneous report was received on from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medication were not provided.   On an unspecified date, the patient was vaccinated with a dose zoster vaccine live (ZOSTAVAX) (dosage regimen was not reported) for the prevention of shingles (herpes zoster).  On an unspecified date, subsequent to the patient vaccination, the patient presented herpes zoster and post herpetic neuralgia. As a direct and proximate result, the patient had been treated by a medical provided. Additionally, the symptoms had been resulted in physical limitation not present prior vaccination. The patient sustained severe and permanent injuries; the patient also experienced mental and emotional distress due to resulting physical limitations and seriousness of patient's conditions.  As a direct and proximate result, the patient suffered serious, progressive, permanent and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury.   The reporter considered the event of herpes zoster and post herpetic neuralgia to be related to zoster vaccine live (ZOSTAVAX).
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 09-NOV-2015, the patient was vaccinated with expired PNEUMOVAX 23 (strength, 25/0.5 (units not reported), dose number, route of administration were not reported, lot # K007824, expire date: 05-NOV-2015). No adverse effect was reported. Additional information has been requested.
Redness and swelling at site of injection, (R) deltoid measured 4" in length and 4.75" in width. Reaction reported on 10/18/12.